AI assistant
KALA BIO, Inc. — Director's Dealing 2020
Jun 30, 2020
35091_dirs_2020-06-29_4b058a88-3e48-41c2-bf2f-d82a10500b91.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2018-05-18
Reporting Person: Paull Robert Bradley (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-18 | Common Stock | J | 597 | — | Acquired | 597 | Indirect |
| 2018-06-11 | Common Stock | J | 477 | — | Acquired | 1074 | Indirect |
| 2020-03-11 | Common Stock | J | 1287 | — | Acquired | 2361 | Indirect |
Footnotes
F1: Pro rata distribution for no consideration to the reporting person from Lux Ventures II, L.P., of which the reporting person is a non-managing member.
F2: Prior reports filed on July 19, 2017 and July 26, 2017 by the reporting person overstated the number of shares beneficially owned by Mr. Paull by 1,204,937 shares by incorrectly reporting that Mr. Paull had beneficial ownership of 1,156,441 shares held directly by Lux Ventures II, L.P. and 48,496 shares held by Lux Ventures II Sidecar, L.P.
F3: These shares are owned directly by The paull Revocable Trust U/A/D 04/06/2012 (the "Trust"), and indirectly by Mr. Paull as co-trustee of the Trust.